Kyverna Therapeutics Inc (KYTX)

$2.94 +0.09 (3.16%)
Market Cap 123.17M
Revenue (ttm) 0.00
Net Income (ttm) -127.48M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 650,100
Avg Vol 322,268
Day's Range N/A - N/A
Shares Out 43.22M
Stochastic %K 76%
Beta 2.52
Analysts Strong Sell
Price Target $17.00

Latest News on KYTX

Kyverna Therapeutics to Present at the Jefferies Global Healthcare Conference

May 28, 2025, 4:02 PM EDT - 8 days ago

Kyverna Therapeutics to Present at the Jefferies Global Healthcare Conference

With Trials In Motion, Cash To 2027, Can Kyverna's Next Data Drop Turn The Stock Around?

May 27, 2025, 3:42 PM EDT - 9 days ago

With Trials In Motion, Cash To 2027, Can Kyverna's Next Data Drop Turn The Stock Around?

Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

May 13, 2025, 4:02 PM EDT - 23 days ago

Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 27, 2025, 4:02 PM EDT - 2 months ago

Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Kyverna: 2 Myasthenia Gravis Program Catalysts On Deck In 2025

Mar 21, 2025, 11:29 AM EDT - 2 months ago

Kyverna: 2 Myasthenia Gravis Program Catalysts On Deck In 2025

Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference

Mar 3, 2025, 4:05 PM EST - 3 months ago

Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference

KYTX Deadline: KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Lawsuit

Feb 7, 2025, 11:42 AM EST - 4 months ago

KYTX Deadline: KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Lawsuit

Investors in Kyverna Therapeutics, Inc. Should Contact The Gross Law Firm Before February 7, 2025 to Discuss Your Rights – KYTX

Feb 6, 2025, 1:51 PM EST - 4 months ago

Investors in Kyverna Therapeutics, Inc. Should Contact The Gross Law Firm Before February 7, 2025 to Discuss Your Rights – KYTX

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics

Feb 5, 2025, 11:54 AM EST - 4 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics

Final Deadline for the Kyverna Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - KYTX

Feb 4, 2025, 3:51 AM EST - 4 months ago

Final Deadline for the Kyverna Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - KYTX

KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Lawsuit

Jan 27, 2025, 3:22 PM EST - 4 months ago

KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Lawsuit

Kyverna Therapeutics Appoints Naji Gehchan, MD, MBA, as Chief Medical and Development Officer

Jan 21, 2025, 4:05 PM EST - 4 months ago

Kyverna Therapeutics Appoints Naji Gehchan, MD, MBA, as Chief Medical and Development Officer

Kyverna Therapeutics to Highlight Near-Term Strategic Priorities and Key Milestones at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 13, 2025, 7:30 AM EST - 5 months ago

Kyverna Therapeutics to Highlight Near-Term Strategic Priorities and Key Milestones at the 43rd Annual J.P. Morgan Healthcare Conference

Kyverna Therapeutics to Present at the 43rd Annual J. P. Morgan Healthcare Conference

Jan 6, 2025, 4:05 PM EST - 5 months ago

Kyverna Therapeutics to Present at the 43rd Annual J. P. Morgan Healthcare Conference